Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT02113800
Brief Title: Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (EVINEC)

First Submitted : April 8, 2014
First Submitted that Met QC Criteria : April 14, 2014
First Posted : April 15, 2014 (Estimate)

Last Update Submitted that Met QC Criteria : March 5, 2019
Last Update Posted : March 6, 2019